Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.
World J Methodol. Sep 20, 2026; 16(3): 118520
Published online Sep 20, 2026. doi: 10.5662/wjm.118520
Published online Sep 20, 2026. doi: 10.5662/wjm.118520
Anti-obesity medications impacting the eye: An emerging concern - a narrative review
Srishti Khullar, Department of Ophthalmology, Military Hospital, Agra 282001, Uttar Pradesh, India
Arvind Kumar Morya, Department of Ophthalmology, All India Institute of Medical Sciences, Hyderabad 508126, Telangana, India
Sarita Aggarwal, Department of Ophthalmology, Santosh Deemed to be University, Ghaziabad, Ghaziabad 201009, Uttar Pradesh, India
Arshi Singh, Department of Ophthalmology, Guru Nanak Eye Center, New Delhi 110001, New Delhi, India
Priya Sisodiya, Department of Ophthalmology, Retina Speciality Eye Hospital, Indore 452010, Madhya Pradesh, India
Rannusha Morya, Department of Psychology, Manipal University, Jaipur 303007, Rajasthan, India
Author contributions: Khullar S, Morya AK, Aggarwal S, Singh A, and Sisodiya P wrote the manuscript; Khullar S, Aggarwal S, Singh A, Sisodiya P, and Morya R contributed to literature search; Khullar S, Morya AK, and Aggarwal S edited and prepared all the necessary documents; Morya AK contributed to final submission. All authors have read and approved the final manuscript.
AI contribution statement: Grammarly was used by the authors only for language polishing, grammar refinement, formatting assistance, and improving the clarity and readability of the manuscript. No portion of the scientific content of the manuscript, including the Abstract, Introduction, Materials and Methods, Results, Discussion, or Conclusion, was generated autonomously by AI. Grammarly was used only for minor grammatical and stylistic corrections. The intellectual content, study concept, clinical observations, methodology, data interpretation, conclusions, and final manuscript decisions were entirely made by the authors. AI tools were not involved in the design of the study, collection of data, analysis of results, clinical interpretation, or formulation of scientific conclusions. No images, figures, clinical photographs, radiological images, or graphical content included in the manuscript were generated by AI. All images are original clinical or diagnostic images obtained and processed by the authors according to standard manuscript preparation practices. The authors have reviewed and approved the final manuscript and take full responsibility for its accuracy, integrity, and scientific content.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Corresponding author: Arvind Kumar Morya, MBBS, MS, MNAMS, Additional Professor, Principal Investigator, Senior Researcher, Department of Ophthalmology, All India Institute of Medical Sciences, Bibi Nagar, Hyderabad 508126, Telangana, India. bulbul.morya@gmail.com
Received: January 6, 2026
Revised: January 17, 2026
Accepted: March 20, 2026
Published online: September 20, 2026
Processing time: 187 Days and 2 Hours
Revised: January 17, 2026
Accepted: March 20, 2026
Published online: September 20, 2026
Processing time: 187 Days and 2 Hours
Core Tip
Core Tip: Anti-obesity medicines are being used more than ever, especially glucagon-like peptide-1 receptor agonists and newer incretin-based therapies. Along with clear metabolic benefits, emerging reports suggest potential eye-related complications such as non-arteritic anterior ischemic optic neuropathy, early worsening of diabetic retinopathy, acute angle closure from uveal effusion, and vitamin A-related visual dysfunction. These risks appear biologically plausible through vascular, metabolic, and neuro-ophthalmic pathways, particularly during rapid weight loss or quick glycaemic change. Clinicians should stratify risk, counsel patients on warning symptoms, and ensure timely ophthalmic evaluation.